extracellular exosome
extracellular exosome
Overview
Extracellular exosomes are small extracellular vesicles released by cells into the extracellular space and found in many body fluids, including human plasma, urine, and nipple discharge. They carry membrane proteins, lipids, and nucleic acids that reflect the molecular state of their parent cells, making them important mediators of intercellular communication and attractive candidates for biomarker discovery, drug delivery, and therapeutic engineering. In biomedical research, exosomes are often discussed together with broader extracellular vesicle populations, but the term specifically refers to a nanoscale vesicular subtype with a defined biogenesis pathway.
From a therapeutic and translational perspective, exosomes are being investigated both as natural delivery vehicles and as disease-associated analytes. Their membrane composition and cargo can be exploited for targeted delivery of drugs, nucleic acids, or genome-editing systems, while their endogenous origin may offer advantages over synthetic carriers. At the same time, their abundance and molecular signatures are being studied for noninvasive sensing strategies in cancer and other diseases, including breast cancer, bladder cancer, and neurological and inflammatory disorders.
Focus of Latest Publications
Recent studies have used extracellular exosomes as both a therapeutic platform and a diagnostic target. In rheumatoid arthritis research, mesenchymal stem cell-derived extracellular vesicles were investigated for their ability to alleviate disease progression in collagen-induced arthritis by modulating autophagy in fibroblast-like synoviocytes. The reported mechanism involved USP21-dependent BRD2 stabilization, highlighting how extracellular vesicle cargo can influence intracellular signaling pathways relevant to inflammatory disease. The publication also emphasized a practical limitation of EVs-MSC: their natural low targeting specificity and insufficient bioactive cargo, which may reduce clinical efficacy.
In cancer diagnostics, exosomes were repeatedly positioned as liquid biopsy targets because they reflect the molecular profile of their parent cells. One study developed a multiplexed peptide-based fluorescent probe platform for analysis of HER2-positive exosomal membrane proteins, using HER2-binding Peptides to interrogate exosomal surface markers. Another study focused on bladder cancer biomarker discovery by high-throughput screening of exosome biomarkers with barcodes integrated herringbone microfluidics, aiming for efficient exosome enrichment and multiplexed biomarker detection. These approaches support the use of exosomes in point-of-care cancer diagnostics and noninvasive sensing strategies.
breast cancer screening was also explored through extracellular vesicles in nipple discharge, where cellulose nanofiber sheets were used to identify EV-associated miRNAs as candidate clinical biomarkers. This work extended the diagnostic utility of exosomes to a minimally invasive sample source. Related exosome-based biomarker concepts were also discussed in the context of HER2-positive disease, reinforcing the role of exosomal membrane proteins as accessible analytes for liquid biopsy.
Exosomes were additionally discussed as delivery vehicles in therapeutic engineering. A study on ssDNA modification of lipid carriers described liposomes and exosomes as nanoscale vesicular structures composed of phospholipids, glycolipids, membrane proteins, and cholesterol, and noted their broad investigation as drug- and nucleic-acid-delivery systems. This aligns with broader work on non-viral delivery approaches, where exosomes were listed alongside lipid nanoparticles, gold nanoparticles, and stimuli-responsive systems such as MMP-cleavable nanoparticles and hypoxia-responsive nanoparticles. In the context of CRISPR-based gene editing and programmable genome engineering, exosomes were highlighted as a potential carrier for delivering editing components, including in efforts related to APOE4 correction in Alzheimer’s disease. The same translational discussion noted persistent barriers such as limited delivery efficiency across the blood-brain barrier, allele specificity, and genomic safety concerns.
Exosomes also appeared in broader reviews of regenerative and senotherapeutic approaches. In diabetic kidney disease, mesenchymal stem/stromal cells and their derived extracellular vesicles were identified among commonly studied cellular therapies, indicating ongoing interest in exosome-mediated tissue repair and anti-senescent effects. Across these studies, exosomes were treated as biologically active vesicles with both diagnostic value and therapeutic promise, but with important challenges in targeting, cargo loading, and clinical translation.